News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why is iHub still showing AMEX?
Probably because the $6.33 price for the last trade on AMEX is a hell of a lot better than the current $4.50 price on NASDAQ, and IHUB wants to keep IBIO investors from sinking into depression. IBIO share price has been on a steady decline since the move to the new exchange.
Some have posted the move to the NASDAQ exchange would be "revealing", while the company CEO tried to spin it as a positive move for investors. So far it's very revealing.
Perhaps someone is investing another six figures here, loading up on cheaper shares as the price continues lower, assuming they have that much remaining after previous catastrophic investments... clicking the BUY button with one hand while eating a slice of delicious Domino's pizza with the other hand.
Notice the sour look on the investor's face. Even a slice of delicious Domino's pizza can't change the fact they've picked another loser investment, and trying to save face by averaging down as the share price continues to tank. No zip code change in this guy's future.
Another great week of IBIO being "revealed". Here's some encouragement and support for the IBIO investor.
Hey...
Why is iHub still showing AMEX?
iBIO got kicked off AMEX
Booted to the CURB
Surprised the 'stock analyst' that has been promoting this stock since $2000 plus is still trying to still sucker noobs.
I missed all the fun.
Did iBIO get booted off AMEX?
Who didn't see that coming?
What tale is iBIO spinning now?
Love the top spin on how that is a positive.
Only ones going 'all in' are flipping gambler's
For my On Topic post of the day I would suggest iBIO would probably make more money in some kind of Molly Maids gig.
Molly Maid Franchise: Average Sales ($855K) vs. Cost ($133K-$191K)
Maybe iBIO could buy Molly Maids with all the cash on hand they have.
Oh wait...
How much do they have left before they dilute again and do another RS?
Very revealing on Nasdaq, yessiree!! I wonder what next week on Nasdaq will reveal.
Yep! Very revealing. Great launch on the new exchange.
tomorrows 3/4/25 NAS uplisting should be revealing
$iBio
That's great, but your chart is the 6-month chart, not the 52-week chart.
Here's the 52 week IBIO chart, showing the new high isn't that much above the high at the start of the period.
Here's the 2-year IBIO chart.
The 3-year IBIO charts looks even worse.
I hope IBIO can find success this time. There are some posting here who were BUY! BUY! BUYING! shares of IBIO at prices at the much higher prices on these longer-term charts, and will have a long way to go before even remotely breaking even. And the multiple reverse splits haven't helped matters for shareholders.
IBIO, new 52 week high
Form 4's - simply stunning quantity of buys from insiders
https://ih.advfn.com/stock-market/AMEX/ibio-IBIO/news
March 4th is iBio's Nasdaq uplisting
thinking they have major news to announce - on top of the Nasdaq milestone uplisting
iBIO...!
Do you think there's a buyout or partnership coming? The 2 new members of the BoD seem to have strong experience in M&A in the Pharma industry.
deep pocket offshore interest
only 9-Mil share float
noice...!
that’s a flexing of their muscles….
absolutely nothing wrong with that move, I’ll take it hands down all day long…!
IBio…!
My dad told me to buy IBIO, can anyone here point me to some useful info or knows what to expect if I invest here ?
Thank you in advance
Best
finally getting some lovin….
9-Mil shares - puny float - will rocket on ant new development
AJMHO
Your bs is done with IBIO Sir!!!
I want tons of $IBIO he he he!!!
Folks, the following song is definitely NOT the official 'Theme Song' for L.A. County, California, right now, Dudes!!!!
IBIO: Thanks for the heads-up, Commander Tw!!!
Otsuka
On February 25, 2024, the Company entered into the PD-1 Purchase Agreement with Otsuka pursuant to which the Company sold and assigned to Otsuka, and Otsuka purchased and assumed, all intellectual property rights directly related to the Company’s PD-1 Assets developed or held for development. The Company received an upfront payment of $1.0 million in cash at closing which is reported as a gain in the fiscal year ended June 30, 2024. The Company will also be eligible to receive additional contingent cash payments totaling up to $52.5 million upon the achievement of certain pre-specified clinical development and commercial milestones. The Company will recognize the potential milestone payments at the earlier of when the contingent consideration is realized or is realizable.
Affiliates of Eastern Capital Limited
On November 1, 2021, the Company and its subsidiary, iBio CDMO LLC (“iBio CDMO”, and collectively with the Company, the “Purchaser”) entered into a series of agreements (the “Transaction”) with College Station Investors LLC (“College Station”), and Bryan Capital Investors LLC (“Bryan Capital” and, collectively with College Station, “Seller”), each affiliates of Eastern Capital Limited (“Eastern,” a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:
(i) acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility’s ground lease;
(ii) acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and
(iii) otherwise terminated all agreements between the Company and the affiliates of Eastern.
The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&M University System (“Texas A&M”) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the “Sublease”) until the consummation of the sale of the Facility.
It's coming......hedge funds buying $IBIO.....
not the same ibio
AI
